Proactive Investors
02 Oct 2026, 06:44 UTC · 10h ago
Verdict
Headline takes no side. We score LLY +0.70 across three claims — strongly bullish.
+0.70strongly bullish
More positive than 82% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish · 3 new · 0 priced in
Eli Lilly's experimental EloraTZP delivered weight loss of up to 23.3% after 48 weeks, outperforming tirzepatide alone at 14.8%.
Newpublished 01 Oct 2026 reporting mid-stage data
So whatThe 8.5% delta in weight loss over tirzepatide puts significant pressure on Novo Nordisk's CagriSema (15.7% at 68 weeks), potentially lowering NVO's long-term market share estimates.
More positive than 93% of claims this week
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
EloraTZP showed poor tolerability with 10.8% to 27.0% of patients discontinuing treatment due to adverse events, versus 2.9% for tirzepatide.
Newpublished 01 Oct 2026 reporting mid-stage data
More negative than 78% of claims this week
Eli Lilly plans to initiate a phase III programme for an EloraTZP co-formulation by the end of 2026.
Newpublished 01 Oct 2026
So whatThe timeline suggests that definitive results on efficacy and tolerability won't be available until 2027 or 2028, delaying a potential catalyst for LLY's multiple.
More positive than 53% of claims this week
Which stocks this story touches
More positive than 82% of ticker scores this week
Reported promising mid-stage data for EloraTZP, demonstrating significant weight loss and blood sugar reduction.
More negative than 78% of ticker scores this week
Faces increased pressure in the obesity market due to promising trial data from a competitor's experimental treatment.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Business Wire
11h ago
−0.7%
Price is moving against the score
$1141.61 vs $1149.85 close before publication (Oct 1) · not market-adjusted
LLY chart →
